NCT02243371 - GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 2, 2015

Primary Completion Date

July 21, 2017

Study Completion Date

July 21, 2017

Conditions

Previously Treated Metastatic Adenocarcinoma of the Pancreas

Interventions

BIOLOGICAL

CRS-207

1 × 10\^9 CFU administered IV on Day 2 of Cycles 3-6

BIOLOGICAL

CRS-207

1 × 10\^9 CFU administered IV on Day 1 of Cycles 3-6

DRUG

nivolumab

3 mg/kg administered IV on Day 1 of Cycles 1-6

BIOLOGICAL

GVAX

5x10\^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2

DRUG

200 mg/m\^2 administered IV on Day 1 of Cycles 1 and 2

Trial Locations (5)

University of Pennsylvania, Philadelphia

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

University of California, San Francisco, San Francisco

Stanford University, Stanford

Providence Portland Medical Center, Portland